nach oben

Digestive Diseases and Sciences

Erschienen in:

01.02.2014 | Review

Indication of Immune Activation in Patients with Perceived Food Hypersensitivity

verfasst von: Gülen Arslan Lied

Erschienen in: Digestive Diseases and Sciences | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Majority of the patients with perceived food hypersensitivity have irritable bowel syndrome (IBS), and a significant proportion of IBS patients also attribute their gastrointestinal complaints to food items. Different factors such as disturbed intestinal fermentation, enteric dysmotility, post-infectious changes and altered microbial flora in the colon as well as psychological disturbances likely play a role in the pathophysiology and symptoms generation in patients with food hypersensitivity. In addition, a number of studies in these patient groups indicate that local, systemic and mucosal immune systems are activated. The question now is no longer intestinal immune activation, but how the immune system is activated in these patients. In the following review, the potential pathogenetic role of the immune system and evidence of immune activation are reported in patients with perceived food hypersensitivity.

Rona RJ, Keil T, Summers C, et al. The prevalence of food allergy: a meta-analysis. J Allergy Clin Immunol. 2007;120:638–646.PubMedCrossRef

Monsbakken KW, Vandvik PO, Farup PG. Perceived food intolerance in subjects with irritable bowel syndrome: etiology, prevalence and consequences. Eur J Clin Nutr. 2006;60:667–672.PubMedCrossRef

Soares RL, Figueiredo HN, Maneschy CP, Rocha VR, Santos JM. Correlation between symptoms of the irritable bowel syndrome and the response to the food extract skin prick test. Braz J Med Biol Res. 2004;37:659–662.PubMed

Lied GA, Lillestøl K, Lind R, et al. Perceived food hypersensitivity: a review of 10 years of interdisciplinary research at a reference centre. Scand J Gastroenterol. 2011;46:1169–1178.PubMedCrossRef

Park MI, Camilleri M. Is there a role of food allergy in irritable bowel syndrome and functional dyspepsia? A systematic review. Neurogastroenterol Motil. 2006;18:595–607.PubMedCrossRef

Barbara G, Zecchi L, Barbaro R, et al. Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome. J Clin Gastroenterol. 2012;46:52–55.CrossRef

Perrier C, Corthesy B. Gut permeability and food allergies. Clin Exp Allergy. 2011;41:20–28.PubMedCrossRef

Macdonald TT, Monteleone G. Immunity, inflammation and allergy in the gut. Science. 2005;307:616–623.CrossRef

Su L, Shen L, Clayburgh DR, et al. Targeted epithelial tight junction dysfunction causes immune activation and contributes to development of experimental colitis. Gastroenterology. 2009;136:551–563.PubMedCentralPubMedCrossRef

10.

Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 2009;9:799–809.PubMedCrossRef

11.

Berstad A, Arslan G, Folvik G. Relationship between intestinal permeability and calprotectin concentration in gut lavage fluid. Scand J Gastroenterol. 2000;35:64–69.PubMedCrossRef

12.

Iqbal TH, Lewis KO, Cooper BT. Diffusion of polyethylene glycol.400 across lipid barriers in vitro. Clin Sci. 1993;85:111–115.PubMed

13.

Schrander JJ, Unsalan-Hooyen RW, Forget PP, Jansen J. [⁵¹Cr] EDTA intestinal permeability in children with cow’s milk intolerance. J Pediatr Gastroenterol Nutr. 1990;10:189–192.PubMedCrossRef

14.

Falth-Magnusson K, Kjellman NI, Odelram H, Sundqvist T, Magnusson KE. Gastrointestinal permeability in children with cow’s milk allergy: effect of milk challenge and sodium cromoglycate as assessed with polyethyleneglycols (PEG 400 and PEG 1000). Clin Allergy. 1986;16:543–551.PubMedCrossRef

15.

Jalonen T. Identical intestinal permeability changes in children with different clinical manifestations of cow’s milk allergy. J Allergy Clin Immunol. 1991;88:737–742.PubMedCrossRef

16.

Ventura MT, Polimeno L, Amoruso AC, et al. Intestinal permeability in patients with adverse reactions to food. Dig Liv Dis. 2006;38:732–736.CrossRef

17.

Lillestøl K, Helgeland L, Helgeland L, Arslan Lied G, et al. Indications of “atopic bowel” in patients with self-reported food hypersensitivity. Aliment Pharmacol Ther. 2010;31:1112–1122.PubMed

18.

Piche T, Barbara G, Aubert P, et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut. 2009;58:196–201.PubMedCrossRef

19.

Martinez C, Vicario M, Ramos L, et al. The jejunum of diarrhea-predominant irritable bowel syndrome shows molecular alterations in the tight junction signaling pathway that are associated with mucosal pathobiology and clinical manifestations. Am J Gastroenterol. 2012;107:736–746.PubMedCrossRef

20.

Coeffier M, Gloro R, Boukhettala N, et al. Increased proteasome-mediated degradation of occludin in irritable bowel syndrome. Am J Gastroenterol. 2010;105:1181–1188.PubMedCrossRef

21.

Bengtsson U, Knutson TW, Knutson L, Dannaeus A, Hallgren R, Ahlstedt S. Eosinophil cationic protein and histamine after intestinal challenge in patients with cow’s milk intolerance. J Allergy Clin Immunol. 1997;100:216–221.PubMedCrossRef

22.

Bischoff SC, Mayer J, Wedemeyer J, et al. Colonoscopic allergen provocation (COLAP): a new diagnostic approach for gastrointestinal food allergy. Gut. 1997;40:745–753.PubMedCrossRef

23.

Bischoff SC, Grabowsky J, Manns MP. Quantification of inflammatory mediators in stool samples of patients with inflammatory bowel disorders and controls. Dig Dis Sci. 1997;42:394–403.PubMedCrossRef

24.

Bischoff SC, Mayer J, Nguyen QT, Stolte M, Manns MP. Immunnohistological assessment of intestinal eosinophil activation in patients with eosinophilic gastroenteritis and inflammatory bowel disease. Am J Gastroenterol. 1999;94:3521–3529.PubMedCrossRef

25.

Kosa L, Kereki E, Borzsonyl L. Copro-eosinophil cationic protein (ECP) in food allergy. Allergy. 1996;51:9.CrossRef

26.

Bischoff SC, Mayer J, Meier PN, Zeck-Kapp G, Manns MP. Clinical significance of the colonoscopic allergen provocation test. Int Arch Allergy Immunol. 1997;113:348–351.PubMedCrossRef

27.

Weidenhiller M, Trankner A, Schwab D, Winterkamp S, Hahn EG, Raithel M. Different kinetics of mediator release can be detected during allergic reactions after oral provocation (double blind placebo-controlled food challenge). Inflamm Res. 2002;51:S29–S30.PubMed

28.

Winterkamp S, Weidenhiller M, Wilken V, et al. Standardised evaluation of urinary excretion of N-tele-methylhistamine in different periods of age in a healthy population. Inflamm Res. 2003;52:S57–S58.PubMedCrossRef

29.

Kumlin M. Measurement of leukotrienes in humans. Am J Respir Crit Care Med. 2000;161:S102–S106.PubMedCrossRef

30.

Andre F, Pene J, Andre C. Interleukin-4 and interferon-gamma production by peripheral blood mononuclear cells from food-allergic patients. Allergy. 1996;51:350–355.PubMed

31.

Hauer AC, Breese EJ, Walker-Smith JA, MacDonald TT. The frequency of cells secreting interferon-gamma and interleukin-4, -5, and -10 in the blood and duodenal mucosa of children with cow’s milk hypersensitivity. Pediatr Res. 1997;42:629–638.PubMedCrossRef

32.

Kondo N, Fukutomi O, Agata H, et al. The role of T lymphocytes in patients with food-sensitive atopic dermatitis. J Allergy Clin Immunol. 1993;91:658–668.PubMedCrossRef

33.

Öhman L, Isakson S, Lindmark AC, et al. T-cell activation in patients with irritable bowel syndrome. Am J Gastroenterol. 2009;104:1205–1212.PubMedCrossRef

34.

O’Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology. 2005;128:541–551.PubMedCrossRef

35.

Cremon C, Gargano L, Morselli-Labate AM, et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol. 2009;104:392–400.PubMedCrossRef

36.

Rutella S, Danese S, Leone G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood. 2006;108:1435–1440.PubMedCrossRef

37.

Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity? Trends Immunol. 2002;23:445–449.PubMedCrossRef

38.

Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science. 1999;284:1835–1837.PubMedCrossRef

39.

Burks AW, Laubach S, Jones SM. Oral tolerance, food allergy and immunotherapy: implications for future treatment. J Allergy Clin Immunol. 2008;121:1344–1350.PubMedCrossRef

40.

Chehade M, Mayer L. Oral tolerance and its relation to food hypersensitivities. J Allergy Clin Immunol. 2005;115:3–1112.PubMedCrossRef

41.

Chadwick VS, Chen WX, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology. 2002;122:1778–1783.PubMedCrossRef

42.

Ohman L, Lindmark AC, Isaksson S, et al. B-cell activation in patients with irritable bowel syndrome (IBS). Neurogastroenterol Motil. 2009;21:644–650.PubMedCrossRef

43.

Lied GA, Vogelsang P, Berstad A, Appel S. Dendritic cell populations in patients with self-reported food hypersensitivity. Int J Gen Med. 2011;4:389–396.PubMedCentralPubMedCrossRef

44.

Mackay F, Browning JL. BAFF: a fundamental survival factor for B cells. Immunology. 2002;2:465–475.PubMed

45.

Lied GA, Berstad A. Functional and clinical aspects of the B-cell activating factor (BAFF): a narrative review. Scand J Immunol. 2011;73:1–7.PubMedCrossRef

46.

Lied GA, Lillestøl K, Valeur J, Berstad A. Intestinal B cell-activating factor (BAFF): an indicator of non-IgE-mediated hypersensitivity reactions to food? Aliment Pharmacol Ther. 2010;32:66–73.PubMedCrossRef

47.

Santos J, Bayarri C, Saperas E, et al. Characterisation of immune mediator release during the immediate response to segmental mucosal challenge in the jejunum of patients with food allergy. Gut. 1999;45:553–558.PubMedCrossRef

48.

Arslan G, Ødegaard S, Elsayed S, Florvaag E, Berstad A. Food allergy and intolerance: response to intestinal provocation monitored by endosonography. Eur J Ultrasound. 2002;15:29–36.PubMedCrossRef

49.

Arslan G, Gilja OH, Lind R, Florvaag E, Berstad A. Response to intestinal provocation monitored by transabdominal ultrasound in patients with food hypersensitivity. Scand J Gastroenterol. 2005;40:386–394.PubMedCrossRef

50.

Arslan G, Lillestøl K, Mulahasanovic A, Florvaag E, Berstad A. Food hypersensitivity reactions visualised by ultrasonography and magnetic resonance imaging in a patient lacking systemic food-specific IgE. Digestion. 2006;73:111–115.PubMedCrossRef

51.

Lin XP, Magnusson J, Ahlstedt S, et al. Local allergic reaction in food-hypersensitive adults despite a lack of systemic food-specific IgE. J Allergy Clin Immunol. 2002;109:879–887.PubMedCrossRef

52.

Crowe SE, Perdue MH. Gastrointestinal food hypersensitivity: basic mechanisms of pathophysiology. Gastroenterology. 1992;103:1075–1095.PubMed

53.

Arslan G, Kahrs GE, Lind R, Frøyland L, Florvaag E, Berstad A. Patients with subjective food hypersensitivity: the value of analysing intestinal permeability and inflammation markers in gut lavage fluid. Digestion. 2004;70:26–35.PubMedCrossRef

54.

Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev. 1997;77:1033–1079.PubMed

55.

Bischoff SC, Wedemeyer J, Herrmann A, et al. Quantitative assessment of intestinal eosinophils and mast cells in inflammatory bowel disease. Histopathology. 1996;28:1–13.PubMedCrossRef

56.

Galli SJ. New insights into “the riddle of the mast cells”: microenvironmental regulation of mast cell development and phenotypic heterogeneity. Lab Invest. 1990;62:5–33.PubMed

57.

Irani AM, Schwartz LB. Mast cell heterogeneity. Clin Exp Allergy. 1989;19:143–155.PubMedCrossRef

58.

Rydning A, Lyng O, Falkmer S, Gronbech JE. Histamine is involved in gastric vasodilation during acid back diffusion via activation of sensory neurons. Am J Physiol Gastrointest Liver Physiol. 2002;283:G603–G611.PubMed

59.

Pothoulakis C, Castagliuolo I, LaMont JT. Nerves and intestinal mast cells modulate responses to enterotoxins. News Physiol Sci. 1998;13:58–63.PubMed

60.

Holzer P, Guth PH. Neuropeptide control of rat gastric mucosal blood flow. Increase by calcitonin gene-related peptide and vasoactive intestinal polypeptide, but not substance P and neurokinin A. Circ Res. 1991;68:100–105.PubMedCrossRef

61.

Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004;126:693–702.PubMedCrossRef

62.

Shea-Donohue T, Stiltz J, Zhao A, Notari L. Mast cells. Curr Gastroenterol Rep. 2010;12:349–357.PubMedCentralPubMedCrossRef

63.

Yu LC. The epithelial gatekeeper against food allergy. Pediatr Neonatol. 2009;50:247–254.PubMedCrossRef

64.

He S, Zhang H, Chen H, et al. Expression and release of IL-29 by mast cells and modulation of mast cell behavior by IL-29. Allergy. 2010;65:1234–1241.PubMedCrossRef

65.

Castellani ML, Kempuraj D, Salini V, et al. The latest interleukin: IL-33 the novel IL-1-family member is a potent mast cell activator. J Biol Regul Homeost Agents. 2009;23:11–14.PubMed

66.

Liew FY, Pitman NI, McInnes IB. Disease-associated functions of IL-33: the new kid in the IL-1 family. Nat Rev Immunol. 2010;10:103–110.PubMedCrossRef

67.

Forbes EE, Groschwitz K, Abonia JP, et al. IL-9—and mast cell mediated intestinal permeability predisposes to oral antigen hypersensitivity. J Exp Med. 2008;205:897–913.PubMedCentralPubMedCrossRef

68.

Barbara G, De Giorgio R, Stanghellini V, Cremon C, Corinaldesi R. A role for inflammation in irritable bowel syndrome? Gut. 2002;51:i41–i44.PubMedCrossRef

69.

Lee KJ, Kim YB, Kim JH, et al. The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol. 2008;23:1689–1694.PubMedCrossRef

70.

Guilarte M, Santos J, de Torres I, et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut. 2007;56:203–209.PubMedCrossRef

71.

Walker MM, Talley NJ, Prabhakar M, et al. Duodenal mastocytosis, eosinophilia and intraepithelial lymphocytosis as possible disease markers in the irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther. 2009;29:765–773.PubMedCrossRef

72.

McKernan DP, Gaszner G, Quigley EM, Cryan JF, Dinan TG. Altered peripheral toll-like receptor responses in the irritable bowel syndrome. Alim Pharmacol Ther. 2011;33:1045–1052.CrossRef

73.

Belmonte L, Youmba SB, Bertiaux-Vandaele N, et al. Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the diseases subtype. PLoS One. 2012;7:e42777.PubMedCentralPubMedCrossRef

74.

Barbara G, Cremon C, Carini G, et al. The immune system in irritable bowel syndrome. J Neurogastroenterol Motil. 2011;17:349–359.PubMedCentralPubMedCrossRef

75.

Chassard C, Dapoigny M, Scott KP, et al. Functional dysbiosis within the gut microbiota of patients with constipated-irritable bowel syndrome. Aliment Pharmacol Ther. 2012;35:828–838.PubMedCrossRef

76.

Bonfrate L, Tack J, Grattagliano I, Cuomo R, Portincasa P. Microbiota in health and irritable bowel syndrome: current knowledge, perspectives and therapeutic options. Scand J Gastroenterol. 2013;48:995–1009.PubMedCrossRef

77.

Bourdu S, Dapoigny M, Chapuy E, et al. Rectal instillation of butyrate provides a novel clinically relevant model of noninflammatory colonic hypersensitivity in rats. Gastroenterology. 2005;128:1996–2008.PubMedCrossRef

78.

Dahlqvist G, Piessevaux H. Irritable bowel syndrome: the role of the intestinal microbiota, pathogenesis and therapeutic targets. Acta Gastroenterol Belg. 2011;74:375–380.PubMed

79.

Fremont M, Coomans D, Massart S, De Meirleir K. High-throughput 16S rRNA gene sequencing reveals alterations of intestinal microbiota in myalgic encephalomyelitis/chronic fatigue syndrome patients. Anaerobe. 2013;22:50–56.PubMedCrossRef

Titel: Indication of Immune Activation in Patients with Perceived Food Hypersensitivity
verfasst von: Gülen Arslan Lied
Publikationsdatum: 01.02.2014
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 2/2014
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-013-2926-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Indication of Immune Activation in Patients with Perceived Food Hypersensitivity

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2014

Third-Line Rescue Therapy with Bismuth-Containing Quadruple Regimen After Failure of Two Treatments (with Clarithromycin and Levofloxacin) for H. pylori Infection

Racial and Ethnic Differences in Health Care Utilization and Outcomes Among Ulcerative Colitis Patients in an Integrated Health-Care Organization

Cyclooxygenase-2 Expression Is Associated with Poor Overall Survival of Patients with Gastric Cancer: A Meta-Analysis

High Serum Vaspin Concentrations in Patients with Ulcerative Colitis

Association Between Facility Characteristics and the Process of Care Delivered to Patients with Hepatitis C Virus Infection

Is Lesion Size an Independent Indication for Endoscopic Resection of Biopsy-Proven Low-Grade Gastric Dysplasia?

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin